TABLE 1.
Clinical trials targeting/relating the CAF in PDAC.
| Drug/Target | Mechanism/Strategy | Clinical trial identifies | Phase |
| Olaptesed pegol (NOX-A12) | CXCL12 inhibitor | NCT03168139 (Completed) | Phase 1/2 |
| Olaptesed pegol (NOX-A12) | CXCL12 inhibitor | NCT03168139(Completed) | Phase 1/2 |
| USL311 | CXCR4 inhibitor | NCT02765165 (Terminated) | Phase 1/2 |
| Plerixafor (AMD3100) | CXCR4 antagonist | NCT03277209 (Terminated) | Phase 1 |
| Plerixafor | CXCR4 Antagonist | NCT03277209(Terminated) | Phase 1 |
| Plerixafor | CXCR4 Antagonist | NCT02179970(Completed) | Phase 1 |
| Plerixafor | CXCR4 Antagonist | NCT04177810 (Recruiting) | Phase 2 |
| Motixafortide (BL-8040) | CXCR4 antagonist | NCT02907099 (Active, not recruiting) | Phase 2 |
| VS-4718 | FAK Inhibitor | NCT02651727(Terminated) | Phase 1 |
| Defactinib | FAK Inhibitor | NCT02758587 (Recruiting) | Phase 1/2 |
| Defactinib | FAK Inhibitor | NCT03727880 (Recruiting) | Phase 2 |
| Galunisertib | TGF-β Receptor I Kinase Inhibitor | NCT02734160(Completed) | Phase 1 |
| M7824 | Bifunctional anti-PD-L1/TGF-β trap | NCT04327986 (Recruiting) | Phase 1/2 |
| M7824 | Bifunctional anti-PD-L1/TGF-β trap | NCT03451773(Completed) | Phase 1/2 |
| Canakinumab | IL-1β inhibitor | NCT04581343 (Recruiting) | Phase 1 |
| Anakinra | IL-1R antagonist | NCT02021422 (Unknown) | Phase 1 |
| Anakinra | IL-1R antagonist | NCT02550327 (Active, not recruiting) | Phase 1 |
| Aldesleukin | IL-2 | NCT01212887 (Terminated) | Phase 1 |
| Aldesleukin | IL-2 | NCT00019084 (Terminated) | Phase 2 |
| BATs Combine With IL-2 and GM-CSF | Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells and Low Dose IL-2 and GM-CSF | NCT02620865 (Active, not recruiting) | Phase 1/2 |
| Siltuximab (CNTO 328) | Anti-IL-6 Monoclonal Antibody | NCT00841191 (Completed) | Phase 1/2 |
| Tocilizumab | anti-IL-6-receptor antibody | NCT02767557 (Recruiting) | Phase 2 |
| IL-12 | Ad5-yCD/mutTKSR39rep-hIL12 adenovirus | NCT03281382 (recruiting) | Phase 1 |
| PEGPH20 | combination with Avelumab | NCT03481920 (Terminated) | Phase 1 |
| PEGPH20 | combination chemotherapy (leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin) | NCT01959139 (Active, not recruiting) | Phase 1/2 |
| PEGPH20 | combined with nab-paclitaxel plus gemcitabine (PAG treatment) | NCT01839487(Completed) | Phase 2 |
| PEGPH20 | combined with nab-paclitaxel plus gemcitabine (PAG treatment) | NCT02715804(Terminated) | Phase 3 |
| Ruxolitinib | JAK signal inhibitor | NCT02119663 (Terminated) | Phase 3 |
| Ruxolitinib | JAK signal inhibitor | NCT02117479 (Terminated) | Phase 3 |
| MK-0646 | IGF1R inhibitor | NCT00769483 (Completed) | Phase 1/2 |
| MM-141 | IGF1R inhibitor | NCT02399137 (Completed) | Phase 2 |
| Ganitumab | IGF1R inhibitor | NCT01231347 (Terminated) | Phase 3 |
| IPI-926 | Hedgehog inhibitor | NCT01383538 (Completed) | Phase 1 |
| VX15/2503 | Anti-SEMA4D Monoclonal Antibody | NCT03373188 (recruiting) | Phase 1 |
| zenocutuzumab (MCLA-128) | anti-NRG1 | NCT02912949 (recruiting) | Phase 1/2 |
| ADC ABBV-085 | an Antibody-Drug Conjugate (ADC) Targeting LRRC15 | NCT02565758 (Completed) | Phase 1 |
| Olaratumab | PDGF-α inhibitor | NCT03086369 (Active, not recruiting) | Phase 1/2 |
CXCL12, chemokine (C-X-C motif) 12; CXCR4, C-X-C motif chemokine receptor 4; FAK, focal adhesion kinase; TGF-β, transforming growth factor-β; IL-1, interleukin-1; GM-CSF, granulocyte/macrophage colony-stimulating factor; PEGPH20, PEGylated recombinant human hyaluronidase; JAK, Janus kinase; IGF1R, insulin-like growth factor 1 receptor; NRG1, neuregulin 1; LRRC15, 15-leucine repeat membrane protein; PDGF-α, platelet-derived growth factor α.